Impact of human papillomavirus types on uterine cervical neoplasia.
cervical cancer
cervical intraepithelial neoplasia
genotype
human papillomavirus
stem cell
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
09 Jun 2024
09 Jun 2024
Historique:
received:
11
05
2024
accepted:
23
05
2024
medline:
10
6
2024
pubmed:
10
6
2024
entrez:
9
6
2024
Statut:
aheadofprint
Résumé
Human papillomavirus (HPV) is a major cause of cervical cancer. As the natural history of HPV-associated cervical lesions is HPV genotype-dependent, it is important to understand the characteristics of these genotypes and to manage them accordingly. Among high-risk HPVs, HPV16 and 18 are particularly aggressive, together accounting for 70% of HPV genotypes detected in cervical cancer. Other than HPV16 and 18, HPV31, 33, 35, 45, 52, and 58 are also at a high risk of progression to cervical intraepithelial neoplasia (CIN)3 or higher. Recent studies have shown that the natural history of HPV16, 18, 52, and 58, which are frequently detected in Japan, depends on the HPV genotype. For example, HPV16 tends to progress in a stepwise fashion from CIN1 to CIN3, while HPV52 and 58 are more likely to persist in the CIN1 to CIN2 state. Among the high-risk HPVs, HPV18 has some peculiar characteristics different from those of other high-risk HPV types; the detection rate in precancerous lesions is much lower than those of other high-risk HPVs, and it is frequently detected in highly malignant adenocarcinoma and small cell carcinoma. Recent findings demonstrate that HPV18 may be characterized by latent infection and carcinogenesis in stem cell-like cells. In this context, this review outlines the natural history of HPV-infected cervical lesions and the characteristics of each HPV genotype.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 23wm0325057h0001
Informations de copyright
© 2024 The Author(s). Journal of Obstetrics and Gynaecology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Obstetrics and Gynecology.
Références
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e190. https://doi.org/10.1016/S2214-109X(19)30488-7
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660
National Cancer Center Japan Cancer registry and statistics (JP). Cancer Information Service. Available from: https://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed Feb 2023
Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–1348. https://doi.org/10.1056/NEJMoa1917338
Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real‐world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021;113(10):1329–1335. https://doi.org/10.1093/jnci/djab080
Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post‐transcriptional regulation. Front Biosci. 2006;11:2286–2302. https://doi.org/10.2741/1971
Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV‐associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319–324. https://doi.org/10.4143/crt.2005.37.6.319
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525–541. https://doi.org/10.1042/CS20050369
Duensing S, Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 2004;109(2):157–162. https://doi.org/10.1002/ijc.11691
Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998;396(6706):84–88. https://doi.org/10.1038/23962
Cosper PF, Hrycyniak LCF, Paracha M, Lee DL, Wan J, Jones K, et al. HPV16 E6 induces chromosomal instability due to polar chromosomes caused by E6AP‐dependent degradation of the mitotic kinesin CENP‐E. Proc Natl Acad Sci USA. 2023 Apr 4;120(14):e2216700120. https://doi.org/10.1073/pnas.2216700120
Jeon S, Allen‐Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol. 1995;69(5):2989–2997. https://doi.org/10.1128/JVI.69.5.2989-2997.1995
McBride AA, Warburton A. The role of integration in oncogenic progression of HPV‐associated cancers. PLoS Pathog. 2017;13(4):e1006211. https://doi.org/10.1371/journal.ppat.1006211
Thain A, Jenkins O, Clarke AR, Gaston K. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J Virol. 1996;70(10):7233–7235. https://doi.org/10.1128/JVI.70.10.7233-7235.1996
Snellenberg S, Schütze DM, Claassen‐Kramer D, Meijer CJ, Snijders PJ, Steenbergen RD. Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex® xMAP™ system. Virology. 2012;422(2):357–365. https://doi.org/10.1016/j.virol.2011.11.006
Ding DC, Chiang MH, Lai HC, Hsiung CA, Hsieh CY, Chu TY. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):215–220. https://doi.org/10.1016/j.ejogrb.2009.08.023
Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, et al. Genome‐wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology‐mediated integration mechanism. Nat Genet. 2015;47(2):158–163. https://doi.org/10.1038/ng.3178
Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus‐associated cancers. Clin Cancer Res. 2015;21(9):2009–2019. https://doi.org/10.1158/1078-0432.CCR-14-1101
Akagi K, Li J, Broutian TR, Padilla‐Nash H, Xiao W, Jiang B, et al. Genome‐wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014;24(2):185–199. https://doi.org/10.1101/gr.164806.113
Shen C, Liu Y, Shi S, Zhang R, Zhang T, Xu Q, et al. Long‐distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region upregulating the allele‐specific MYC expression in HeLa cells. Int J Cancer. 2017 Aug 1;141(3):540–548. https://doi.org/10.1002/ijc.30763
Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Cancer Genome Atlas NetworkCharacterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci USA. 2014;111(43):15544–15549. https://doi.org/10.1073/pnas.1416074111
Kusakabe M, Taguchi A, Tanikawa M, Hoshi D, Tsuchimochi S, Qian X, et al. Application of organoid culture from HPV18‐positive small cell carcinoma of the uterine cervix for precision medicine. Cancer Med. 2023;12(7):8476–8489. https://doi.org/10.1002/cam4.5588
McIntyre JB, Wu JS, Craighead PS, Phan T, Köbel M, Lees‐Miller SP, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013;128(3):409–414. https://doi.org/10.1016/j.ygyno.2012.12.019
Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol. 2007;105(3):662–666. https://doi.org/10.1016/j.ygyno.2007.01.045
Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz‐Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371–375. https://doi.org/10.1038/nature12881
Araldi RP, Assaf SMR, Carvalho RF, Carvalho MACR, Souza JM, Magnelli RF, et al. Papillomaviruses: a systematic review. Genet Mol Biol. 2017;40(1):1–21. https://doi.org/10.1590/1678-4685-GMB-2016-0128
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.
Li N, Franceschi S, Howell‐Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–935. https://doi.org/10.1002/ijc.25396
Demarco M, Hyun N, Carter‐Pokras O, Raine‐Bennett TR, Cheung L, Chen X, et al. A study of type‐specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. https://doi.org/10.1016/j.eclinm.2020.100293
Ikegami T, Kise N, Kinjyo H, Kondo S, Suzuki M, Tsukahara N, et al. Development of antibodies against HPV‐6 and HPV‐11 for the study of laryngeal papilloma. Viruses. 2021;13(10):2024. https://doi.org/10.3390/v13102024
Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta‐analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–1799. https://doi.org/10.1086/657321
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Retrospective International Survey and HPV Time Trends Study GroupHuman papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. https://doi.org/10.1016/S1470-2045(10)70230-8
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. https://doi.org/10.1002/ijc.30716
Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta‐analysis. Lancet Oncol. 2014;15(12):1319–1331. https://doi.org/10.1016/S1470-2045(14)70471-1 Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.
Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta‐analysis. Lancet Infect Dis. 2018;18(2):198–206. https://doi.org/10.1016/S1473-3099(17)30653-9
Perkins RB, Wentzensen N, Guido RS, Schiffman M. Cervical cancer screening: a review. JAMA. 2023;330(6):547–558. https://doi.org/10.1001/jama.2023.13174
Australian Government Department of Health and Aged Care. National Cervical Screening Program – Understanding the National Cervical Screening Program Management Pathway. https://www.health.gov.au/resources/publications/national‐cervical‐screening‐program‐understanding‐the‐national‐cervical‐screening‐program‐management‐pathway?language=en. Accessed May 2024
Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, et al. Japan HPV And Cervical Cancer Study GroupPredicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer. 2011;128(12):2898–2910. https://doi.org/10.1002/ijc.25630
Taguchi A, Hara K, Tomio J, Kawana K, Tanaka T, Baba S, et al. Multistate Markov model to predict the prognosis of high‐risk human papillomavirus‐related cervical lesions. Cancers (Basel). 2020;12(2):270. https://doi.org/10.3390/cancers12020270
Ikesu R, Taguchi A, Hara K, Kawana K, Tsuruga T, Tomio J, et al. Prognosis of high‐risk human papillomavirus‐related cervical lesions: a hidden Markov model analysis of a single‐center cohort in Japan. Cancer Med. 2022;11(3):664–675. https://doi.org/10.1002/cam4.4470
Azuma Y, Kusumoto‐Matsuo R, Takeuchi F, Uenoyama A, Kondo K, Tsunoda H, et al. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol. 2014;44(10):910–917. https://doi.org/10.1093/jjco/hyu112
Bulk S, Berkhof J, Rozendaal L, Fransen Daalmeijer NC, Gök M, de Schipper FA, et al. The contribution of HPV18 to cervical cancer is underestimated using high‐grade CIN as a measure of screening efficiency. Br J Cancer. 2007;96(8):1234–1236. https://doi.org/10.1038/sj.bjc.6603693
Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, et al. Human papillomavirus infections among Japanese women: age‐related prevalence and type‐specific risk for cervical cancer. Cancer Sci. 2009;100(7):1312–1316. https://doi.org/10.1111/j.1349-7006.2009.01161.x
Vänskä S, Luostarinen T, Lagheden C, Eklund C, Kleppe SN, Andrae B, et al. Differing age‐specific cervical cancer incidence between different types of human papillomavirus: implications for predicting the impact of elimination programs. Am J Epidemiol. 2021;190(4):506–514. https://doi.org/10.1093/aje/kwaa121
Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high‐grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132(4):854–867. https://doi.org/10.1002/ijc.27713
Collins SI, Constandinou‐Williams C, Wen K, Young LS, Roberts S, Murray PG, et al. Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. Cancer Res. 2009;69(9):3828–3832. https://doi.org/10.1158/0008-5472.CAN-08-3099
Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services; Barretos Cancer Hospital; Baylor College of Medicine; Beckman Research Institute of City of Hope et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378–384. https://doi.org/10.1038/nature21386
Lagström S, Løvestad AH, Umu SU, Ambur OH, Nygård M, Rounge TB, et al. HPV16 and HPV18 type‐specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples. Tumour Virus Res. 2021;12:200221. https://doi.org/10.1016/j.tvr.2021.200221
Toyohara Y, Taguchi A, Ishii Y, Yoshimoto D, Yamazaki M, Matsunaga H, et al. Identification of target cells of human papillomavirus 18 using squamocolumnar junction organoids. Cancer Sci. 2024;115(1):125–138. https://doi.org/10.1111/cas.15988
Kusakabe M, Taguchi A, Tanikawa M, Wagatsuma R, Yamazaki M, Tsuchimochi S, et al. Cells with stem‐like properties are associated with the development of HPV18‐positive cervical cancer. Cancer Sci. 2023;114(3):885–895. https://doi.org/10.1111/cas.15664
Baba S, Taguchi A, Kawata A, Hara K, Eguchi S, Mori M, et al. Differential expression of human papillomavirus 16‐, 18‐, 52‐, and 58‐derived transcripts in cervical intraepithelial neoplasia. Virol J. 2020;17(1):32. https://doi.org/10.1186/s12985-020-01306-0
Maru Y, Kawata A, Taguchi A, Ishii Y, Baba S, Mori M, et al. Establishment and molecular phenotyping of organoids from the squamocolumnar junction region of the uterine cervix. Cancers (Basel). 2020;12(3):694. https://doi.org/10.3390/cancers12030694